For example, on the treatment of NY-ESO 1+ NSCLC, where atezolizumab was combined with both the adjuvant poly-ICLC (a synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid and poly-L-lysine double-stranded RNA) and DEC-205/NY-ESO-1 [CDX-1401, a fusion protein between a mAb directed against the endocytic DC receptor DEC-205, linked to the tumor-associated antigen (NY-ESO-1)] (NCT02495636) (217). Here, LY75 is linked to non-small cell lung carcinoma.